UBS 18/02/2010 1 Buy $41.10 20.9%
A good operational result, obscured by swine flu and plasma margin growth with profits up 23%, UBS says.
In terms of outlook, UBS feels its all about plasma and the 4-year roll out of Privigen margin improvements.
While the 1H result was, solid, the broker feels share price gains will be step by step.
credit suisse - $40.50, page-3
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$309.51 |
Change
-1.820(0.58%) |
Mkt cap ! $149.9B | |||
| Open | High | Low | Value | Volume |
| $308.51 | $310.46 | $307.85 | $18.36M | 59.47K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3 | $309.42 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $309.68 | 43 | 5 |
View Market Depth
| Last trade - 10.52am 30/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |